Navigation Links
Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models
Date:11/3/2008

ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publication of preclinical results for 2ME2 (Panzem(R) or 2- methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr. Ernest Brahn, Professor of Medicine, Rheumatology Program Director, David Geffen School of Medicine at UCLA, were published in the November 2008 issue of the Journal of Rheumatology (Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, and Plum SM. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses synovial VEGF and bFGF gene expression. J Rheumatol 2008;35:2119- 28).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Results from treatment studies in a preclinical model of established rheumatoid arthritis demonstrated that daily oral administration of 2ME2 suppressed both clinical and radiographic indicators of joint inflammation and damage, including soft tissue swelling and bone erosion. The treatment benefits of 2ME2 were dose-dependent and associated with reduced joint expression of the prominent angiogenic growth factors, FGF-2 and VEGF, as well as decreased angiogenesis. The report further demonstrates both a delay in onset and decrease in severity of arthritis if 2ME2 treatment is started prior to disease initiation. These results indicate that 2ME2 may represent a novel agent for treatment of inflammatory autoimmune diseases such as rheumatoid arthritis and identify 2ME2 as a disease mod
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
2. Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
3. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
4. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
5. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
6. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
7. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
8. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
9. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
10. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
11. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the Netherlands ... His Majesty Willem-Alexander, King of the Netherlands, has announced ... POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant in ... will take part in the Grand Opening Ceremony to ... p.m. and tour the plant. POET-DSM is a joint ...
(Date:8/21/2014)... Aug. 21, 2014 Mathematic studies at the ... , and funded by the Jeffrey Epstein VI Foundation ... can be visually identified for elimination. These aggressive cells are ... which shows a topological map of what to look for ... research, for while tumor cells can be extracted from biopsy, ...
(Date:8/21/2014)... Pursuit Solutions ( http://www.pursuit-solutions.com ), a ... for Life Sciences sales and marketing organizations, announced ... Commercial Sales Models” by Peter Robinson, co-founder and ... examines some innovative models used to improve sales ... the pharmaceutical market. Robinson grades the industry on ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2RENU 28 Skin Care Now Available in Australia and New Zealand 2
... there was a monopoly phone service prior to the 1984 ... exclusivity in the territory and we will provide universal service ... a geographic subscriber base, the traditional phone companies ensured that ... fair price. There was one price across the board. That ...
... - Does the Wisconsin Alumni Research Foundation's ... for approval? , ,The foundation's stem cell patent is ... it is overly broad and is suppressing scientific research. ... the more than 300 academic licenses it has issued ...
... to clarify the definition of records for the treatment ... incorporate them into Electronic Health Records, has been signed ... 650 creates an exception to current law pertaining to ... to mental health records when they are treating patients ...
Cached Biology Technology:Does redefining universal service help bridge the digital divide? 2Does redefining universal service help bridge the digital divide? 3Does redefining universal service help bridge the digital divide? 4Does redefining universal service help bridge the digital divide? 5WARF stem cell patent faces long and winding road 2WARF stem cell patent faces long and winding road 3WARF stem cell patent faces long and winding road 4WARF stem cell patent faces long and winding road 5
(Date:8/22/2014)... a leading source of information for businesses and professionals, ... Riverside in its 2014 list of "some of the ... generate the list, the company analyzed citation data over ... has had enormous impact. , The following UC Riverside ... the greatest number of highly cited papers in one ...
(Date:8/22/2014)... NAIROBI (22 August 2014)With ... as a major threat to food security across the continent, ... five years, 1.7 million African farmers in 13 countries have ... helped them double or even triple crop yields. , The ... (AGRA) focuses on intensive efforts initiated five years ago to ...
(Date:8/22/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Grant Writing Seminar & Practical Exercises Workshop which will ... Maryland from August 25-26, 2014. These awards are ... research scientists from underrepresented groups in the the FASEB ... year MARC conferred 11 awards totaling $20,350. , The ...
Breaking Biology News(10 mins):5 UC Riverside scientists among world's most influential scientific minds 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4
... next generation sequencing (NGS) and Certified Service Provider for ... a leading company in complex analysis and interpretation of ... complete human exome array, based on Roche NimbleGen sequence ... comprehensive service for human exome capture, targeted re-sequencing and ...
... be used to "see" something as small as an ... has once again overturned conventional wisdom. Secretary of Energy, ... National Laboratory (Berkeley Lab) Steven Chu led the development ... microscopy to ,image objects or the distance between them ...
... of all acute leukemias represents a small population of ... standard treatments available today. Though current chemotherapy can produce ... of experiencing a recurrence and dying from the disease. ... rare form of leukemia called acute promyelocytic leukemia (APL), ...
Cached Biology News:Eurofins MWG Operon and Genomatix developed most complete human exome array 2Correcting a trick of the light brings molecules into view 2Correcting a trick of the light brings molecules into view 3Correcting a trick of the light brings molecules into view 4Grant to fund research into eradicating the leukemia stem cell 2
Request Info...
Request Info...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
...
Biology Products: